scholarly journals Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies

2019 ◽  
Vol 121 (2) ◽  
pp. 402-409 ◽  
Author(s):  
Koji Matsuo ◽  
Shinya Matsuzaki ◽  
Rachel S. Mandelbaum ◽  
Kazuhide Matsushima ◽  
Maximilian Klar ◽  
...  
2019 ◽  
Vol 26 (7) ◽  
pp. 1316-1326 ◽  
Author(s):  
Nicolò Bizzarri ◽  
Vito Chiantera ◽  
Alfredo Ercoli ◽  
Anna Fagotti ◽  
Lucia Tortorella ◽  
...  

2013 ◽  
Vol 130 (1) ◽  
pp. e109-e110
Author(s):  
V. Andikyan ◽  
F. Khoury-Collado ◽  
E. Hobeika ◽  
S. Lee ◽  
N. Abu-Rustum ◽  
...  

2013 ◽  
Vol 23 (5) ◽  
pp. 923-928 ◽  
Author(s):  
Vaagn Andikyan ◽  
Fady Khoury-Collado ◽  
Samith Sandadi ◽  
William P. Tew ◽  
Roisin E. O’Cearbhaill ◽  
...  

ObjectiveIt is well documented that recurrence after pelvic exenteration remains high (up to 50%), and patients may require a prolonged period of recuperation following this aggressive surgery. We conducted a retrospective review to evaluate the feasibility of administering adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.MethodsWe reviewed the medical records of patients with any gynecologic cancer who underwent exenterative surgery between January 2005 and February 2011 at our institution. Patients were referred for postexenteration adjuvant chemotherapy based on surgeon’s discretion and/or presence of high-risk features: positive margins, positive lymph nodes, and/or lymphovascular space invasion. Suitability for chemotherapy was assessed by a gynecologic medical oncologist. Regimens consisted of 4 to 6 cycles of platinum-based doublet chemotherapy. Chemotherapy-related toxicities were assessed using the Common Terminology Criteria for Adverse Events version 4.ResultsWe identified 42 patients who underwent pelvic exenteration during the study period. Eleven (26%) were referred for adjuvant chemotherapy. Three (27%) of the 11 patients did not receive chemotherapy because of delayed postoperative recovery or physician choice. Seven (88%) of the remaining 8 patients completed all scheduled chemotherapy. Grade 2 toxicities or greater were documented in 6 patients (75%), the most common being neutropenia, neuropathy, and fatigue. Median follow-up time was 25 months (range, 6–56 months). The 3-year progression-free and overall survival rates of the 8 patients who received chemotherapy were 58% (95% confidence interval, 18%–84%) and 54% (95% confidence interval, 13%– 83%), respectively.ConclusionsThe administration of adjuvant chemotherapy is feasible for a select group of patients after pelvic exenteration for gynecologic malignancies. Our results need to be interpreted with caution because of the small and heterogeneous cohort of patients included.


2008 ◽  
Vol 26 (28) ◽  
pp. 4626-4633 ◽  
Author(s):  
Karl Y. Bilimoria ◽  
David J. Bentrem ◽  
Joseph M. Feinglass ◽  
Andrew K. Stewart ◽  
David P. Winchester ◽  
...  

Purpose Quality-improvement initiatives are being developed to decrease volume-based variability in surgical outcomes. Resources for national and hospital quality-improvement initiatives are limited. It is unclear whether quality initiatives in surgical oncology should focus on factors affecting perioperative mortality or long-term survival. Our objective was to determine whether differences in hospital surgical volume have a larger effect on perioperative mortality or long-term survival using two methods. Patients and Methods From the National Cancer Data Base, 243,103 patients who underwent surgery for nonmetastatic colon, esophageal, gastric, liver, lung, pancreatic, or rectal cancer were identified. Multivariable modeling was used to evaluate 60-day mortality and 5-year conditional survival (excluding perioperative deaths) across hospital volume strata. The number of potentially avoidable perioperative and long-term deaths were calculated if outcomes at low-volume hospitals were improved to those of the highest-volume hospitals. Results Risk-adjusted perioperative mortality and long-term conditional survival worsened as hospital surgical volume decreased for all cancer sites, except for liver resections where there was no difference in survival. When comparing low- with high-volume hospitals, the hazard ratios for perioperative mortality were substantially larger than for long-term survival. However, the number of potentially avoidable deaths each year in the United States, if outcomes at low-volume hospitals were improved to the level of highest-volume centers, was significantly larger for long-term survival. Conclusion Although the magnitude of the hazard ratios implies that quality-improvement efforts should focus on perioperative mortality, a larger number of deaths could be avoided by focusing quality initiatives on factors associated with long-term survival.


2013 ◽  
Vol 129 (3) ◽  
pp. 586-592 ◽  
Author(s):  
Irene A. Burger ◽  
Hebert Alberto Vargas ◽  
Olivio F. Donati ◽  
Vaagn Andikyan ◽  
Evis Sala ◽  
...  

2011 ◽  
Vol 21 (2) ◽  
pp. 397-402 ◽  
Author(s):  
Matías Jurado ◽  
Juan Luis Alcazar ◽  
Jorge Baixauli ◽  
Jose Luis Hernandez-Lizoain

Objective:To study risk factors for low colorectal anastomotic leak after pelvic exenteration for gynecologic malignancies.Methods:Data from 60 patients, 32 with ovarian cancer and 28 with nonovarian cancer who underwent pelvic exenteration with colorectal anastomosis (CRA) were retrospectively analyzed.Results:Overall rate of CRA leak was 20%. The CRA leak was associated with type of tumor (3% for the ovarian cancer and 40.8% for the nonovarian cancer,P= 0.004), CRA height (<5 cm vs ≥5 cm, 75% vs 6.3%;P= 0.001), and previous radiotherapy (RT; 53.3% vs 8.9%;P= 0.001). Multivariate analysis showed that only previous RT and CRA height were associated with the CRA leak. Rectosigmoid wall involvement (81.8% vs 27%;P= 0.001) and mesorectum infiltration (69.2% vs 21.7%;P= 0.001) were more frequent among patients with ovarian cancer patients.Conclusion:Previous RT and CRA at or less than 5 cm from the anal verge pose a high risk for CRA leak. In these cases, a definitive colostomy should be recommended.


2022 ◽  
pp. 101702
Author(s):  
Dimitrios Haidopoulos ◽  
Vasilios Pergialiotis ◽  
Kyveli Aggelou ◽  
Nikolaos Thomakos ◽  
Nikolaos Alexakis ◽  
...  

2021 ◽  
Vol 41 (6) ◽  
pp. 3037-3043
Author(s):  
EVA KATHARINA EGGER ◽  
HANNA LIESENFELD ◽  
MATTHIAS B. STOPE ◽  
FLORIAN RECKER ◽  
ANNA DÖSER ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document